Project Grant K99MH144561
- Federal Grant Award Summary Baylor College of Medicine received a $778,543 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) to conduct a neurophysiological investigation of the approach-avoidance axis in obsessive-compulsive disorder (OCD) with applications to neuromodulation therapies. The award, dated August 1, 2025, supports a five-year research initiative (through July 31, 2030) designed to develop a mechanistic...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded McLean Hospital Corporation a $1,457,610 Project Grant effective July 1, 2025, through April 30, 2030, under the Mental Health Research Grants program (CFDA 93.242). The research project investigates the synaptic mechanisms of continuous theta burst stimulation (CTBS), an FDA-cleared inhibitory repetitive transcranial magnetic stimulation (rTMS) protocol used to treat treatment-resistant depression. The primary...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of Florida a Project Grant of $151,761 under the Mental Health Research Grants program (CFDA 93.242) for the period May 15, 2026, through May 14, 2028. The research aims to develop and validate advanced computational indices based on resting electroencephalogram (EEG) recordings as objective biomarkers for obsessive-compulsive and anxiety disorders. The project will establish reliable,...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded Massachusetts General Hospital a $824,728 Project Grant on March 25, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct advanced neuroimaging research characterizing intracortical feedforward and feedback sensory processes in Autism Spectrum Disorder (ASD). The research will employ a multimodal neuroimaging approach combining magnetoencephalography (MEG) with millisecond...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Harvard Medical School a $674,028 Project Grant under the Mental Health Research Grants program (CFDA 93.242) beginning May 1, 2026, and extending through January 31, 2031. The award funds research investigating the determinants and function of tonic dopamine signaling in the striatum, with the primary deliverable being scientific insights into how dopamine levels regulate action selection and behavioral...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Boston Children's Hospital a $990,550 Project Grant under the Mental Health Research Grants program (CFDA 93.242) effective March 10, 2026, with completion targeted for February 29, 2028. This R61/R33 phased research award will develop and test a computer-based cognitive control and metacognition training intervention designed to reduce restricted and repetitive behaviors in school-aged children with autism...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Massachusetts General Hospital a Project Grant totaling $183,118 on September 1, 2025, under the Mental Health Research Grants program (CFDA 93.242). Under the direction of Dr. Tubbs, this research initiative will deliver integrated genomic and electronic health record (EHR) analyses designed to advance precision psychiatry by addressing critical gaps in translating genetic findings to clinical practice. The...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $150,104 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded December 30, 2025, with a completion date of June 30, 2028. The grant funds basic neuroscience research investigating intracellular signaling dynamics and synaptic responses in the external globus pallidus (GPE), a critical hub nucleus in the basal ganglia that...
- Federal Grant Award Summary Virtuallybetter Health LLC received a $449,958 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded on September 12, 2025, with completion targeted for August 31, 2026. The award supports development and scaled implementation of OC-GO, an interactive digital health platform designed to improve treatment adherence and clinical outcomes for Obsessive Compulsive Disorder (OCD) patients...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded The Feinstein Institutes for Medical Research a Project Grant of $519,558 under the Mental Health Research Grants program (CFDA 93.242), effective June 15, 2025 through April 30, 2030. The research project focuses on identifying and validating cerebellar-cortical circuitry biomarkers as predictive indicators of antipsychotic treatment response in first-episode psychosis patients. The primary deliverables...
Summary of Federal Project Grant Award The National Institute of Mental Health (NIMH) awarded a Project Grant totaling $129,195 to Massachusetts General Hospital (MGH) on May 21, 2026, under the Mental Health Research Grants program (CFDA 93.242). The research project, titled "Electrophysiological Biomarkers to Guide Deep Brain Stimulation Treatment in Obsessive-Compulsive Disorder," will be completed by April 30, 2028. This award supports translational neuroscience research aimed at establishing ventral capsule/ventral striatum (VC/VS) alpha oscillations as an objective biomarker for obsessive-compulsive disorder (OCD) symptom states, addressing a critical clinical need for approximately 20% of OCD patients who remain treatment-resistant despite standard therapeutic interventions. The research will deliver products and findings through rigorous investigation of chronic neural oscillations recorded directly from deep brain stimulation electrodes in freely moving patients. Specifically, the project will determine whether fluctuations in VC/VS alpha oscillations systematically track real-world transitions between symptomatic and non-symptomatic states by integrating at-home DBS recordings, wearable sensor-based behavioral tracking, and ecological momentary assessments. The anticipated outcomes include empirical validation of neural biomarkers for OCD, methodological advances in sensing-enabled DBS technology, and clinical translation protocols to reduce trial-and-error DBS programming while improving treatment accessibility for eligible OCD patients.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $129.2k | 5/26/26 |